Uğur Şahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

Covid-19 roundup: Pfiz­er/BioN­Tech add on vac­cine da­ta for young chil­dren; Mex­i­co says it's miss­ing vac­cine dos­es from UN

A three-dose vac­cine se­ries was 73.2% ef­fec­tive in pre­vent­ing Covid-19 for chil­dren be­tween 6 months and 4 years old, Pfiz­er and BioN­Tech said Tues­day morn­ing.

The ef­fi­ca­cy up­date comes af­ter Pfiz­er and BioN­Tech’s vac­cine was au­tho­rized for emer­gency use in the youngest age group in June. That au­tho­riza­tion was sup­port­ed by in­ter­im da­ta that sug­gest­ed the vac­cine se­ries was 80% ef­fec­tive, with 10 symp­to­matic Covid cas­es in the vac­cine co­hort.

The fi­nal ef­fi­ca­cy re­sults came af­ter 21 cas­es of symp­to­matic in­fec­tion. The da­ta, how­ev­er, came with a wide con­fi­dence in­ter­val of 43.8% to 87.6% ef­fi­ca­cy.

Pfiz­er and BioN­Tech not­ed that the tri­al was con­duct­ed when Omi­cron BA.2 was dom­i­nant and when BA.4 and BA.5 were still emerg­ing, so the ef­fi­ca­cy re­sults against the lat­ter two strains were in­con­clu­sive.

Mex­i­co to file com­plaint to UN over miss­ing Covid shots

In a press con­fer­ence Mon­day, Mex­i­can Pres­i­dent An­dres Manuel López Obrador said his gov­ern­ment would file a com­plaint to the UN for not de­liv­er­ing Covid-19 vac­cines it paid for up­front.

López Obrador said the UN still owes Mex­i­co $75 mil­lion in vac­cines. Mex­i­co had or­dered vac­cines through a UN and WHO ini­tia­tive known as CO­V­AX, which was cre­at­ed to ac­cel­er­ate eq­ui­table ac­cess to Covid-19 vac­cines.

Ac­cord­ing to a UN CO­V­AX track­er, Mex­i­co is owed over 26 mil­lion dos­es and has re­ceived 24.6 mil­lion.

Russ­ian re­search in­sti­tute an­nounces new ver­sion of Sput­nik V adapt­ed to Delta and Omi­cron

Fol­low­ing the foot­steps of oth­er vac­cine de­vel­op­ers, the Gama­leya Re­search In­sti­tute — a Russ­ian med­ical re­search cen­ter — and the Russ­ian Di­rect In­vest­ment Fund (RDIF) have cre­at­ed a new Sput­nik V vac­cine that is adapt­ed to Delta and Omi­cron.

The orig­i­nal Sput­nik vac­cine was the first to be ap­proved by any coun­try, but Rus­sia’s in­va­sion of Ukraine like­ly quashed any fu­ture for that vac­cine, as the US and EU sanc­tioned RDIF. Ac­cord­ing to a World Trade Or­ga­ni­za­tion track­er, Sput­nik V has made up a mere 2% of the glob­al vac­cine mar­ket as of May.

Mod­er­na and Pfiz­er are both work­ing on bi­va­lent vac­cines that tar­get Omi­cron. Mod­er­na’s bi­va­lent vac­cine nabbed EU au­tho­riza­tion last week, and Pfiz­er said it has sub­mit­ted an EUA for its bi­va­lent vac­cine, with a sub­mis­sion to Eu­ro­pean au­thor­i­ties to fol­low in the com­ing days.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Catal­ent to cut about 200 jobs in Mary­land and Texas

Contract manufacturing company Catalent is cutting about 200 jobs in Maryland and Texas, according to WARN notices, trimming back some of its pandemic-era expansion.

The company will cut 77 jobs by Jan. 15 of next year at a cell therapy facility in Webster, TX, just outside of Houston. In Maryland, the company is reducing staff at two locations, with 82 jobs being eliminated at Catalent’s facility in Gaithersburg, and 53 in Rockville. The layoffs go into effect at those locations on Jan. 14.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

iECURE CEO Joe Truitt and founder Jim Wilson

Jim Wil­son biotech iECURE gets fresh $65M to push pe­di­atric liv­er dis­ease gene ther­a­py in­to the clin­ic

Jim Wilson-founded biotech iECURE has wrapped a $65M Series A extension round to get its lead candidate — a gene replacement therapy for a rare inherited liver disease known as ornithine transcarbamylase deficiency, or OTC — into the clinic.

This round was co-led by Novo Holdings and LYFE Capital, followed by initial investors Versant and OrbiMed as well. In September 2021, iECURE raised a $50 million Series A led by the latter two. The new cash infusion will get iECURE through an initial in-human trial, which CEO Joe Truitt told Endpoints News iECURE hopes to read out in 2024.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Tim Walbert, Horizon Therapeutics CEO (via YouTube)

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Amgen, J&J’s Janssen and Sanofi are all in talks to acquire Horizon Therapeutics, the rare disease biotech disclosed late Tuesday.

Horizon confirmed “highly preliminary discussions” with those companies regarding a potential buyout offer after the Wall Street Journal reported takeover interest.

Although the company — which commands a market cap of close to $18 billion — emphasized that “there can be no certainty that any offer will be made for the Company,” shares $HZNP still surged 31% in after-hours trading to near $103, bringing it to the point where it started the year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Sana, Codex­is lay off staff, reshuf­fle pipeline in bid to fo­cus cell ther­a­py, en­zyme en­gi­neer­ing work

As its market cap shrinks to a fraction of its heyday, flashy cell therapy startup Sana Biotechnology is laying off 15% of its staffers in a move to rejig the pipeline and restructure the company.

Sana is among a growing group of biotechs that, feeling the weight of a broader market downturn and seeing their shares tumble steadily, are tightening the purse strings and adjusting their focus. Also on Tuesday, Codexis, an enzyme engineering company based in California and now helmed by former Sierra Oncology CEO Stephen Dilly, announced it will reduce the workforce by 18%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

John Carroll with David Chang, Allogene CEO (Credit: Jeff Rumans Photography)

Al­lo­gene takes the stage in New York to go deep on its off-the-shelf cell ther­a­pies — de­clar­ing a first for sol­id tu­mors

NEW YORK — In most cases, a biotech like Allogene would wait until the next big science conference to offer its latest series of snapshots of its data. But most biotechs aren’t like Allogene, where the veteran leaders from Kite garnered a substantial number of kudos over the years for their in-depth reviews of the company’s progress.

So on Tuesday, the leaders at Allogene converged on Manhattan once again to give a detailed breakdown of their latest steps forward, looking to stay out front in the busy off-the-shelf cell therapy arena, keep a clean bill of health on the safety front and prove that they can not only match the autologous pioneers they helped create but make the all-important leap into solid tumors. It’s another step forward in a journey that has a long way to go before even the first big regulatory finish lines appear on the track. But for CEO David Chang, who spent some time with me running through the data ahead of the Tuesday session, it all amounts to forward momentum toward the desired goal.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.